Question

In: Accounting

Sole the follwing problem Statement of cash flows—indirect method The comparative balance sheet of Livers Inc....

Sole the follwing problem

Statement of cash flowsindirect method

The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows:

1

Dec. 31, 20Y3

Dec. 31, 20Y2

2

Assets

3

Cash

$625,650.00

$586,340.00

4

Accounts receivable (net)

228,170.00

208,030.00

5

Inventories

641,480.00

617,130.00

6

Investments

0.00

240,290.00

7

Land

328,170.00

0.00

8

Equipment

706,070.00

552,300.00

9

Accumulated depreciation-equipment

(165,580.00)

(147,010.00)

10

Total assets

$2,363,960.00

$2,057,080.00

11

Liabilities and Stockholders’ Equity

12

Accounts payable (merchandise creditors)

$424,300.00

$404,860.00

13

Accrued expenses payable (operating expenses)

41,850.00

52,880.00

14

Dividends payable

23,200.00

19,880.00

15

Common stock, $4 par

153,000.00

99,000.00

16

Paid-in capital: Excess of issue price over par—common stock

418,000.00

279,800.00

17

Retained earnings

1,303,610.00

1,200,660.00

18

Total liabilities and stockholders’ equity

$2,363,960.00

$2,057,080.00

Additional data obtained from an examination of the accounts in the ledger for 20Y3 are as follows:

A. The investments were sold for $280,680 cash.
B. Equipment and land were acquired for cash.
C. There were no disposals of equipment during the year.
D. The common stock was issued for cash.
E. There was a $199,210 credit to Retained Earnings for net income.
F. There was a $96,260 debit to Retained Earnings for cash dividends declared.

Prepare a statement of cash flows, using the indirect method of presenting cash flows from operating activities. Refer to the Labels and Amount Descriptions list provided for the exact wording of the answer choices for text entries. Be sure to complete the heading of the statement. Use the minus sign to indicate cash out flows, cash payments, decreases in cash, or any negative adjustments.

Labels and Amount Descriptions

Labels and Amount Descriptions
Cash paid for dividends
Cash paid for merchandise
Cash paid for purchase of equipment
Cash paid for purchase of land
Cash received from customers
Cash received from sale of common stock
Cash received from sale of investments
Change in cash
December 31, 20Y3
Decrease in accounts payable
Decrease in accounts receivable
Decrease in accrued expenses payable
Decrease in inventories
Depreciation
For the Year Ended December 31, 20Y3
Gain on sale of investments
Increase in accounts payable
Increase in accounts receivable
Increase in accrued expenses payable
Increase in inventories
Loss on sale of investments
Net cash flow from operating activities
Net cash flow used for operating activities
Net cash flow from investing activities
Net cash flow used for investing activities
Net cash flow from financing activities
Net cash flow used for financing activities
Net income
Net loss

Solutions

Expert Solution

Livers Inc
Statement of Cash flows
For the Year Ended November 30, 20Y3
Cash flows from operating activities
Net Income   $   199,210
Adjustments to reconcile net income to ;
Depreciation expense $      18,570 165580-147010
Gain on sale of investment $   (40,390) 240290-280680
Increase in accounts receivable $   (20,140) 208030-228170
Increase in inventories $   (24,350) 617130-641480
Increase in accounts payable $      19,440 424300-404860
Decrease in accrued expense payable $   (11,030) 41850-52880
$   (57,900)
Net cash provided by operating activities $   141,310
Cash flows from investing activities
Cash paid for purchase of equipment $ (153,770) 552300-706070
Cash paid for purchase of land $ (328,170)
Cash received from sale of investment $   280,680
Net cash used by investing activities $ (201,260)
Cash flows from financing activities
Payment of cash dividend $   (92,940) 23200-19880-96260
Cash received from issuance of common stock $   192,200 153000-99000+418000-279800
Net cash provided by financing activities $      99,260
Net Increase in cash and cash equivalents $      39,310
Cash and cash equivalents at beginning of period $   586,340
Cash and cash equivalents at end of period $   625,650

You can reach me over comment box if you have any doubts. Please rate this answer


Related Solutions

Sole the follwing problem Statement of cash flows—indirect method The comparative balance sheet of Livers Inc....
Sole the follwing problem Statement of cash flows—indirect method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: 1 Dec. 31, 20Y3 Dec. 31, 20Y2 2 Assets 3 Cash $625,650.00 $586,340.00 4 Accounts receivable (net) 228,170.00 208,030.00 5 Inventories 641,480.00 617,130.00 6 Investments 0.00 240,290.00 7 Land 328,170.00 0.00 8 Equipment 706,070.00 552,300.00 9 Accumulated depreciation-equipment (165,580.00) (147,010.00) 10 Total assets $2,363,960.00 $2,057,080.00 11 Liabilities and Stockholders’ Equity 12 Accounts payable (merchandise...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $300,080 $277,530 Accounts receivable (net) 108,710 99,680 Inventories 306,860 295,120 Investments 0 114,340 Land 157,400 0 Equipment 338,580 260,920 Accumulated depreciation—equipment (79,270) (70,360) Total assets $1,132,360 $977,230 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $204,960 $192,510 Accrued expenses payable (operating expenses) 20,380 25,410 Dividends payable 11,320 8,800 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $222,990 $209,100 Accounts receivable (net) 80,780 75,100 Inventories 228,030 222,360 Investments 0 86,140 Land 116,960 0 Equipment 251,600 196,590 Accumulated depreciation—equipment (58,900) (53,010) Total assets $841,460 $736,280 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $152,300 $145,050 Accrued expenses payable (operating expenses) 15,150 19,140 Dividends payable 8,410 6,630 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $256,050 $240,660 Accounts receivable (net) 92,760 86,430 Inventories 261,850 255,910 Investments 0 99,140 Land 134,310 0 Equipment 288,900 226,250 Accumulated depreciation—equipment (67,640) (61,010) Total assets $966,230 $847,380 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $174,890 $166,930 Accrued expenses payable (operating expenses) 17,390 22,030 Dividends payable 9,660 7,630 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $292,970 $275,040 Accounts receivable (net) 106,130 98,780 Inventories 299,610 292,480 Investments 0 113,310 Land 153,670 0 Equipment 330,560 258,580 Accumulated depreciation—equipment (77,390) (69,730) Total assets $1,105,550 $968,460 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $200,100 $190,790 Accrued expenses payable (operating expenses) 19,900 25,180 Dividends payable 11,060 8,720 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $313,010 $292,180 Accounts receivable (net) 113,390 104,940 Inventories 320,110 310,700 Investments 0 120,370 Land 164,180 0 Equipment 353,170 274,690 Accumulated depreciation—equipment (82,680) (74,070) Total assets $1,181,180 $1,028,810 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $213,790 $202,680 Accrued expenses payable (operating expenses) 21,260 26,750 Dividends payable 11,810 9,260 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $241,460 $226,680 Accounts receivable (net) 87,470 81,410 Inventories 246,920 241,060 Investments 0 93,390 Land 126,650 0 Equipment 272,440 213,110 Accumulated depreciation—equipment (63,780) (57,470) Total assets $911,160 $798,180 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $164,920 $157,240 Accrued expenses payable (operating expenses) 16,400 20,750 Dividends payable 9,110 7,180 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $291,640 $273,170 Accounts receivable (net) 105,650 98,110 Inventories 298,250 290,480 Investments 0 112,540 Land 152,980 0 Equipment 329,060 256,820 Accumulated depreciation—equipment (77,040) (69,250) Total assets $1,100,540 $961,870 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $199,200 $189,490 Accrued expenses payable (operating expenses) 19,810 25,010 Dividends payable 11,010 8,660 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $301,740 $281,660 Accounts receivable (net) 109,310 101,160 Inventories 308,580 299,510 Investments 0 116,040 Land 158,270 0 Equipment 340,460 264,800 Accumulated depreciation—equipment (79,710) (71,410) Total assets $1,138,650 $991,760 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $206,100 $195,380 Accrued expenses payable (operating expenses) 20,500 25,790 Dividends payable 11,390 8,930 Common stock,...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3...
Statement of Cash Flows—Indirect Method The comparative balance sheet of Livers Inc. for December 31, 20Y3 and 20Y2, is shown as follows: Dec. 31, 20Y3 Dec. 31, 20Y2 Assets Cash $256,770 $237,750 Accounts receivable (net) 93,020 85,390 Inventories 262,580 252,830 Investments 0 97,950 Land 134,680 0 Equipment 289,710 223,520 Accumulated depreciation—equipment (67,830) (60,280) Total assets $968,930 $837,160 Liabilities and Stockholders' Equity Accounts payable (merchandise creditors) $175,380 $164,920 Accrued expenses payable (operating expenses) 17,440 21,770 Dividends payable 9,690 7,530 Common stock,...
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT